Previous issue | Next issue | Archive | Cover PDF
Volume 2 (5); 2012
Editorial
Molecular Imaging and Radiotherapy: Theranostics for Personalized Patient Management
Irina Velikyan
Theranostics 2012; 2(5): 424-426. doi:10.7150/thno.4428
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Research Paper
Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide
Ebrahim S. Delpassand, Amin Samarghandi, Jennifer Sims Mourtada, Sara Zamanian, Gregory D. Espenan, Roozbeh Sharif, Shawn MacKenzie, Kambiz Kosari, Omar Barakat, Shagufta Naqvi, John E. Seng, Lowell Anthony
Theranostics 2012; 2(5): 472-480. doi:10.7150/thno.3739
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Reviews
How Does the Patient Benefit from Clinical PET?
Jens Sörensen
Theranostics 2012; 2(5): 427-436. doi:10.7150/thno.3794
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
Richard P. Baum, Harshad R. Kulkarni
Theranostics 2012; 2(5): 437-447. doi:10.7150/thno.3645
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)
Kjell Öberg
Theranostics 2012; 2(5): 448-458. doi:10.7150/thno.3931
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Radiolabeled Peptides: Valuable Tools for the Detection and Treatment of Cancer
M. Fani, H. R. Maecke, S. M. Okarvi
Theranostics 2012; 2(5): 481-501. doi:10.7150/thno.4024
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Imaging Key Biomarkers of Tumor Angiogenesis
Marina V. Backer, Joseph M. Backer
Theranostics 2012; 2(5): 502-515. doi:10.7150/thno.3623
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Imaging of Adrenal Masses with Emphasis on Adrenocortical Tumors
Anders Sundin
Theranostics 2012; 2(5): 516-522. doi:10.7150/thno.3613
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Pretargeted Molecular Imaging and Radioimmunotherapy
David M. Goldenberg, Chien-Hsing Chang, Edmund A. Rossi, William J. McBride, Robert M. Sharkey
Theranostics 2012; 2(5): 523-540. doi:10.7150/thno.3582
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]
Case Report
Lessons on Tumour Response: Imaging during Therapy with 177Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma
Ulrike Garske, Mattias Sandström, Silvia Johansson, Dan Granberg, Hans Lundqvist, Mark Lubberink, Anders Sundin, Barbro Eriksson
Theranostics 2012; 2(5): 459-471. doi:10.7150/thno.3594
[Abstract]
[Full text]
[PDF] [PubMed]
[PMC]